1st Quarter - Report

GEPHARDT GROUP GOVERNMENT AFFAIRS for HEALIANCE PHARMACEUTICALS

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

innovative diabetes treatment

Foreign entity interest: Foreign entity Digen Pharmaceuticals will benefit from FDA approval of the product.

LobbyistCovered position, as disclosed
JANICE O'CONNELL —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Pharmacy PHA

innovative diabetes treatment

Foreign entity interest: Foreign entity Digen Pharmaceuticals will benefit from FDA approval of the product.

LobbyistCovered position, as disclosed
JANICE O'CONNELL —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Foreign Relations FOR

innovative diabetes treatment

Foreign entity interest: Foreign entity Digen Pharmaceuticals will benefit from FDA approval of the product.

LobbyistCovered position, as disclosed
JANICE O'CONNELL —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.